In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and bloc···【more】
Release date:2024-08-08Recommended:460
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date:2024-08-08Recommended:534
Exkivity effectively inhibits the growth and spread of tumor cells by precisely ···【more】
Release date:2024-08-08Recommended:498
Capmatinib is a MET inhibitor developed by Novartis specifically for patients wi···【more】
Release date:2024-08-08Recommended:482
Exkivityis an innovative third-representative dermal growth factor receptor (EGF···【more】
Release date:2024-08-08Recommended:428
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, prim···【more】
Release date:2024-08-08Recommended:472
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer···【more】
Release date:2024-08-08Recommended:566
Exkivity is a broad-spectrum inhibitor that broadly inhibits multiple mutant kin···【more】
Release date:2024-08-08Recommended:497
Exkivity is a new type of targeted therapy for lung cancer, which is a third rep···【more】
Release date:2024-08-08Recommended:488
Exkivity is a novel oral anti-cancer drug that acts as a small molecule tyrosine···【more】
Release date:2024-08-08Recommended:513
Capmatinib can be used to treat patients with METex14-mutated non-small cell lun···【more】
Release date:2024-08-07Recommended:487
Capmatinib is an oral MET inhibitor that received Breakthrough Therapy Designati···【more】
Release date:2024-08-07Recommended:539